Last reviewed · How we verify

SonoVue-enhanced ultrasound

Bracco Diagnostics, Inc · Phase 3 active Small molecule

SonoVue-enhanced ultrasound is a Ultrasound contrast agent Small molecule drug developed by Bracco Diagnostics, Inc. It is currently in Phase 3 development for Enhancement of ultrasound imaging for detection and characterization of focal lesions in liver, breast, and other organs, Assessment of myocardial perfusion and left ventricular opacification in echocardiography. Also known as: sulfur hexafluoride microbubbles.

SonoVue is a microbubble contrast agent that enhances ultrasound imaging by reflecting ultrasound waves, improving visualization of blood flow and tissue perfusion.

SonoVue is a microbubble contrast agent that enhances ultrasound imaging by reflecting ultrasound waves, improving visualization of blood flow and tissue perfusion. Used for Enhancement of ultrasound imaging for detection and characterization of focal lesions in liver, breast, and other organs, Assessment of myocardial perfusion and left ventricular opacification in echocardiography.

At a glance

Generic nameSonoVue-enhanced ultrasound
Also known assulfur hexafluoride microbubbles
SponsorBracco Diagnostics, Inc
Drug classUltrasound contrast agent
ModalitySmall molecule
Therapeutic areaDiagnostic Imaging
PhasePhase 3

Mechanism of action

SonoVue consists of sulfur hexafluoride microbubbles stabilized by a phospholipid shell. When injected intravenously, these microbubbles circulate through the vasculature and strongly reflect ultrasound waves, creating enhanced contrast in ultrasound images. This allows clinicians to better visualize perfusion patterns, detect lesions, and assess tissue viability in real-time.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SonoVue-enhanced ultrasound

What is SonoVue-enhanced ultrasound?

SonoVue-enhanced ultrasound is a Ultrasound contrast agent drug developed by Bracco Diagnostics, Inc, indicated for Enhancement of ultrasound imaging for detection and characterization of focal lesions in liver, breast, and other organs, Assessment of myocardial perfusion and left ventricular opacification in echocardiography.

How does SonoVue-enhanced ultrasound work?

SonoVue is a microbubble contrast agent that enhances ultrasound imaging by reflecting ultrasound waves, improving visualization of blood flow and tissue perfusion.

What is SonoVue-enhanced ultrasound used for?

SonoVue-enhanced ultrasound is indicated for Enhancement of ultrasound imaging for detection and characterization of focal lesions in liver, breast, and other organs, Assessment of myocardial perfusion and left ventricular opacification in echocardiography.

Who makes SonoVue-enhanced ultrasound?

SonoVue-enhanced ultrasound is developed by Bracco Diagnostics, Inc (see full Bracco Diagnostics, Inc pipeline at /company/bracco-diagnostics-inc).

Is SonoVue-enhanced ultrasound also known as anything else?

SonoVue-enhanced ultrasound is also known as sulfur hexafluoride microbubbles.

What drug class is SonoVue-enhanced ultrasound in?

SonoVue-enhanced ultrasound belongs to the Ultrasound contrast agent class. See all Ultrasound contrast agent drugs at /class/ultrasound-contrast-agent.

What development phase is SonoVue-enhanced ultrasound in?

SonoVue-enhanced ultrasound is in Phase 3.

What are the side effects of SonoVue-enhanced ultrasound?

Common side effects of SonoVue-enhanced ultrasound include Headache, Flushing, Chest discomfort, Nausea, Hypersensitivity reactions.

Related